Clinical update: Proteasome inhibitors in hematologic malignancies

Cancer Treatment Reviews

Volumn 29, Issue SUPPL. 1, 2003, Pages 33-39

  Richardson, Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bortezomib; Hematologic malignancies; Multiple myeloma; Proteasome inhibition

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; BORTEMOZIB; BORTEZOMIB; CELL ADHESION MOLECULE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MELPHALAN; PROTEASOME INHIBITOR; THALIDOMIDE; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLEEDING; CANCER CELL; CANCER CELL CULTURE; CANCER RECURRENCE; CELL PROTECTION; CHEMOSENSITIVITY; CLINICAL TRIAL; CONSTIPATION; CYTOKINE PRODUCTION; DIARRHEA; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPONATREMIA; IN VIVO STUDY; LEUKOPENIA; MALAISE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0038528620     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00080-X     Document Type: Review

References (25)

1. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82(1): 110-122.
2. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100(1): 11-17.
3. Cusack Jr JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition. Cancer Res 2001; 61(9): 3535-3540.
4. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61(7): 3071-3076.
5. Ma MH, Parker KM, Manyak S, et al. Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway. Blood 2001; 98(11): 437a.
6. Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001; 50(1): 183-193.
7. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-κB in the biology and treatment of multiple myeloma. Semin Oncol 2001; 28(6): 626-633.
8. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62(17): 4996-5000.
9. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93(5): 1658-1667.
10. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996; 87(3): 1104-1112.
11. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 2(5): 493-506.
12. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 2003; 101(4): 1530-1534.
13. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2002; published online.
14. Pham L, Tamayo A, Lo P, Yoshimura L, Ford RJ. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 2001; 98(11): 465a.
15. Schenkein D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin Lymphoma 2002; 3(1): 49-55.
16. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194(12): 1861-1874.
17. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001; 61(15): 5926-5932.
18. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59(11): 2615-2622.
19. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20(21): 4420-4427.
20. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8(8): 2505-2511.
21. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102(5): 1115-1123.
22. Richardson P, Barlogie B, Berenson J, et al. A phase II multicenter study of the proteasome inhibitor bortezomib (Velcade™ formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease. Blood 2002; 100(11): 104a.
23. Richardson PG, Barlogie B, Berenson J, et al. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (pts) with relapsed/ refractory disease: results from cohort 1 analysis. Proceedings of the American Society of Clinical Oncology-38th Annual Meeting 2002; 21: 11a.
24. Jagannath S, Barlogie B, Berenson J, et al. A phase II multicenter randomized study of the proteasome inhibitor bortezomib (VELCADE™, formerly PS-341) in multiple myeloma (MM) patients (pts) relapsed after front-line therapy. Blood 2002; 100(11): 812a.
25. Papandreou C, Daliani D, Millikan RE, et al. Phase I study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (Pts) with advanced malignancies. Proceedings of the American Society of Clinical Oncology-37th Annual Meeting 2001; 20: 86a.